BTK and mantle cell lymphoma: To confirm the diverse response of these MCL cell lines to BTK inhibition, we also evaluated its impact on cell cycle progression using the second-generation BTK inhibitor ACP-196 at a low dose of 25 nM (Fig. 1b and Supplemental Fig. S1).